title: Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS.
abstract: Virend (SP-303), a new topical antiviral agent with activity against herpesvirus, was evaluated in a multicenter, double-blind, placebo-controlled Phase II study for safety and effectiveness against recurrent genital herpes lesions in patients with AIDS. The primary endpoints of this study were complete healing of lesions and time to healing. Patients had a history of recurrent genital or anogenital herpes with at least one lesion and positive HSV culture at enrollment. Participants received Virend (15% ointment; 24 patients) or matching placebo (21 patients) three times a day for 21 days. Excluding two patients in the Virend group who received an initial treatment but were lost to follow-up, 9 of 22 (41%) patients treated with Virend experienced complete healing of their lesions compared with three (14%) patients in the placebo group (P = 0.053). Viral culture revealed that 50% of Virend-treated patients and 19% of placebo-treated patients became culture-negative during treatment (P = 0.06). Based on these preliminary clinical findings, further evaluation of Virend for topical treatment of genital herpes in patients with AIDS is planned.
authors.affiliation: Instituto Nacional de la Nutricion, Delegacion Tlalpan, Mexico, D.F.
authors.forename: R
authors.initials: R
authors.lastname: Orozco-Topete
authors.forename: J
authors.initials: J
authors.lastname: Sierra-Madero
authors.forename: C
authors.initials: C
authors.lastname: Cano-Dominguez
authors.forename: J
authors.initials: J
authors.lastname: Kershenovich
authors.forename: G
authors.initials: G
authors.lastname: Ortiz-Pedroza
authors.forename: E
authors.initials: E
authors.lastname: Vazquez-Valls
authors.forename: C
authors.initials: C
authors.lastname: Garcia-Cosio
authors.forename: A
authors.initials: A
authors.lastname: Soria-Cordoba
authors.forename: A M
authors.initials: AM
authors.lastname: Armendariz
authors.forename: X
authors.initials: X
authors.lastname: Teran-Toledo
authors.forename: J
authors.initials: J
authors.lastname: Romo-Garcia
authors.forename: H
authors.initials: H
authors.lastname: Fernandez
authors.forename: E J
authors.initials: EJ
authors.lastname: Rozhon
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000473:pathology; D000287:Administration, Topical; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001004:Anus Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000821:virology; D001704:Biopolymers / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D002392:Catechin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015394:Molecular Structure; D010146:Pain / Q000188:drug therapy; D013997:Time Factors; D017201:Virus Shedding; D044945:Proanthocyanidins
chemical_list: D000998:Antiviral Agents; D001704:Biopolymers; D002392:Catechin; C546704:crofelemer; D044945:Proanthocyanidins